Free Trial

Analysts Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $28.00

Smith & Nephew SNATS logo with Medical background

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) has earned an average recommendation of "Hold" from the six analysts that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation. The average 1 year price target among analysts that have issued a report on the stock in the last year is $28.00.

SNN has been the topic of several research analyst reports. Canaccord Genuity Group raised their price objective on Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Hsbc Global Res downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. UBS Group lowered shares of Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Finally, HSBC downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th.

Get Our Latest Stock Report on Smith & Nephew SNATS

Institutional Investors Weigh In On Smith & Nephew SNATS

A number of hedge funds have recently added to or reduced their stakes in the stock. River Road Asset Management LLC grew its holdings in Smith & Nephew SNATS by 64.0% in the 4th quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider's stock worth $49,947,000 after buying an additional 792,829 shares in the last quarter. J. Goldman & Co LP acquired a new position in Smith & Nephew SNATS during the 4th quarter worth $47,700,000. Goldman Sachs Group Inc. boosted its position in Smith & Nephew SNATS by 49.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider's stock worth $50,255,000 after acquiring an additional 583,809 shares during the period. Armistice Capital LLC grew its stake in shares of Smith & Nephew SNATS by 258.1% in the first quarter. Armistice Capital LLC now owns 1,769,000 shares of the medical equipment provider's stock worth $50,187,000 after purchasing an additional 1,275,000 shares in the last quarter. Finally, Brandes Investment Partners LP increased its holdings in shares of Smith & Nephew SNATS by 11.4% during the fourth quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider's stock valued at $33,504,000 after purchasing an additional 138,994 shares during the period. 25.64% of the stock is currently owned by institutional investors.

Smith & Nephew SNATS Stock Performance

Shares of SNN traded up $0.66 during mid-day trading on Wednesday, hitting $31.35. The stock had a trading volume of 1,051,030 shares, compared to its average volume of 817,559. Smith & Nephew SNATS has a fifty-two week low of $23.69 and a fifty-two week high of $31.72. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62. The company has a market cap of $13.73 billion, a PE ratio of 14.52, a PEG ratio of 0.92 and a beta of 0.69. The company's fifty day simple moving average is $29.24 and its two-hundred day simple moving average is $27.37.

Smith & Nephew SNATS Company Profile

(Get Free Report

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

Recommended Stories

Analyst Recommendations for Smith & Nephew SNATS (NYSE:SNN)

Should You Invest $1,000 in Smith & Nephew SNATS Right Now?

Before you consider Smith & Nephew SNATS, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew SNATS wasn't on the list.

While Smith & Nephew SNATS currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines